Sexual function after vaginal erbium laser: the results of a large, multicentric, prospective study

Gambacciani, Marco; Albertin, E; Torelli, M; Bracco, Gian Luca; Casagrande, A C; Martella, Lucia; Baiocchi, G.; Alfieri, S; Russo, Novella; Cervigni, Mauro

doi:10.1080/13697137.2020.1804544

Cited by 12 publications

(21 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 114 papers were included according to the eligibility criteria listed above. Of these, 111 studies investigated GSM, VVA, UI, and LS symptoms as primary indication (Tables 3–6); 15 RCT, 23–37 87 cohort studies, 38–124 eight case reports, 125–132 one case‐control study, 133 including a total of 9000 women, not accounting for overlap between the studies. Additionally, three cross‐sectional studies focused solely on the characteristics of AEs 134–136 .…”

Section: Resultsmentioning

confidence: 99%

“…Of the included studies, 81 studies investigated CO 2 ‐LASER from different manufacturers 23–31,33,35,36,38–58,66–93,95–104,122–125,128–131,133,136 . Twenty‐eight studies investigated Er:YAG LASER from different manufacturers 32,34,59–65,94,107–121,127,132,135 . Three studies reported on CO 2 or Er:YAG simultaneously 105,126,134 .…”

Section: Resultsmentioning

confidence: 99%

“…Thirty‐six studies on the effect of vaginal LASER on GSM were identified through this review (Table 3). 23,24,26–28,38–65,70,125,133 The studies included 4220 women with study sizes ranging from 4 to 1081 women with a median (IQR) of 60.5 (42.25–75.25) women. Among these studies, 29 studies investigated the effect of CO 2 LASER, 23–28,38–58,125,133 counting six RCTs including 336 women 23–28 , and 21 cohort studies including 2251 women 38–58 .…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

The evidence behind the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: A state‐of‐the‐art review

Mortensen

Christensen

Løkkegaard

2022

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

In recent years, LASER has been introduced as a minimally invasive treatment for a broad range of vaginal and vulvar symptoms and diseases. However, the efficacy and safety of vaginal and vulvar LASER has continuously been questioned. The aim of this study is to create an overview of the current literature and discuss the controversies within the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus. A search string was built in PubMed.The search was commenced on August 25, 2021 and closed on October 27, 2021. Two authors screened the studies in Covidence for inclusion according to the eligibility criteria in the protocol. The data were extracted from the studies and are reported inThe authors set up an internal protocol to use as a guideline for the review, listing the criteria and outcomes for this review. The eligibility criteria for this state-of-the-art review adhered to the principals of PICO-participants, interventions, comparison and outcome. Studies that investigated the effect of any vaginal and vulvar LASER on women with symptoms of GSM, VVA, UI or LS were eligible for inclusion. No outcome restrictions were applied.Only original studies were included; unpublished work, editorials, conference abstracts, reviews and meta-analysis were excluded.Likewise, in vivo studies on animals, histologic cohort studies, and studies of the effect of radiofrequency treatment were excluded.indications as a treatment should be kept on a research level until further high-quality evidence is available.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The evidence behind the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: A state‐of‐the‐art review

Mortensen

Christensen

Løkkegaard

2022

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

“…Several published studies have shown that multiple GSM symptoms are greatly reduced when using the Er:YAG SMOOTH, laser and that the results are comparable and last longer than local vaginal estrogen. [2][3][4][5] Even with no change in vaginal epithelial thickness the treated women reported excellent symptom relief, which should be the ultimate goal of any GSM treatment.…”

Section: Sirmentioning

confidence: 92%

“…The Er:YAG laser with SMOOTH mode stimulates tissue turnover and also induces vasodilatation and angiogenesis, resulting in increased vaginal lubrication and better tissue quality. Several published studies have shown that multiple GSM symptoms are greatly reduced when using the Er:YAG SMOOTH, laser and that the results are comparable and last longer than local vaginal estrogen 2–5 . Even with no change in vaginal epithelial thickness the treated women reported excellent symptom relief, which should be the ultimate goal of any GSM treatment.…”

mentioning

confidence: 95%

Re: Vaginal Er:YAG laser application in the menopausal ewe model: a randomised estrogen and sham‐controlled trial

Gaspar

Gambacciani

2021

BJOG

View full text Add to dashboard Cite

show abstract

Vaginal erbium laser treatment for stress urinary incontinence: A multicenter randomized sham‐controlled clinical trial

O'Reilly,

Viereck,

Phillips

et al. 2023

Intl J Gynecology & Obste

View full text Add to dashboard Cite

ObjectiveTo evaluate the efficacy and safety of non‐ablative vaginal Er:YAG laser device in stress urinary incontinence (SUI) treatment.MethodsWe conducted a multicenter blinded randomized sham‐controlled trial in which women with urodynamic SUI were randomization to active arm using Er:YAG laser therapy, and sham arm using sham handpiece. Patients received two treatments 1 month apart. The primary outcomes measure was 1 h pad weight test measured at 6 months. Secondary outcomes were durability of treatment success at 12 months, and questionnaires for assessment of SUI severity (ICIQ‐UI SF), sexual function (PISQ‐12) and HRQoL (KHQ), and incidence and severity of device related adverse events and pain (VAS).ResultsA total of 110 participants with SUI were recruited; 73 in the active arm and 37 in the sham arm. Two participants were excluded; one was assigned the wrong treatment and one withdrew their consent. Treatment success was observed in 36% of the sham arm and 59% of the active arm; in the latter, odds of achieving treatment success were more than three‐fold higher (OR 3.63, 95% CI: 1.3–11.2, P = 0.02). HRQoL by KHQ showed significant improvement in the active versus the sham arm (OR 0.36, 95% CI: 0.15–0.87, P = 0.003). Similarly, subjective patient assessment of general and sexual function improvement with PISQ‐12 and PGI‐I showed superior effect over sham (OR 2.8, 95% CI: 1.2–7.0, P = 0.02 and OR 0.13, 95% CI: 0.05–0.36, P < 0.001, respectively).ConclusionNon‐ablative vaginal Er:YAG laser therapy significantly improves SUI symptoms versus sham treatment. Er:YAG laser therapy should be considered as a non‐surgical treatment option for SUI patients.

show abstract

Sexual function after vaginal erbium laser: the results of a large, multicentric, prospective study

Cited by 12 publications

References 21 publications

The evidence behind the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: A state‐of‐the‐art review

The evidence behind the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: A state‐of‐the‐art review

Re: Vaginal Er:YAG laser application in the menopausal ewe model: a randomised estrogen and sham‐controlled trial

Vaginal erbium laser treatment for stress urinary incontinence: A multicenter randomized sham‐controlled clinical trial

Contact Info

Product

Resources

About